Table 2 Treatment patterns at baseline
From: Time-dependent effect of GLP-1 receptor agonists on cardiovascular benefits: a real-world study
| Â | Primary prevention | Secondary prevention |
|---|---|---|
Ongoing anti-diabetic treatments before baseline visit | ||
Metformin | 343 (86.8%) | 129 (83.2%) |
Pioglitazone | 68 (17.2%) | 23 (14.8%) |
Acarbose | 5 (1.3%) | 2 (1.3%) |
Sulfonylureas or meglitinides | 145 (36.7%) | 50 (32.3%) |
Insulin | 83 (21%) | 43 (27.7%) |
SGLT2 inhibitors | 12 (3.0%) | 5 (3.2%) |
DPP4 inhibitors | 92 (23.3%) | 33 (21.3%) |
Cardioactive therapies at baseline | ||
Statins | 177 (44.8%) | 140 (90.3%) |
Ezetimibe | 17 (4.3%) | 19 (12.3%) |
PCSK-9 inhibitors | 0 | 1 (0.6%) |
Antiplatelet agents | 113 (28.6%) | 147 (94.8%) |
Anti-hypertensives | 282 (71.4%) | 151 (97.4%) |
ACEi o ARBs o MRAs | 244 (61.8%) | 132 (85.2%) |
GLP-1 RA prescribed at baseline | ||
Lixisenatide | 1 (0.3%) | 0 |
Exenatide BID | 6 (1.5%) | 1 (0.6%) |
Exenatide LAR | 4 (1.0%) | 0 |
Liraglutide | 247 (62.5%) | 92 (59.4%) |
Dulaglutide | 134 (33.9%) | 62 (40%) |
Semaglutide (weekly) | 3 (0.8%) | 0 |